Nothing Special   »   [go: up one dir, main page]

AR099470A1 - Vacunas de virus de aves de corral líquidas - Google Patents

Vacunas de virus de aves de corral líquidas

Info

Publication number
AR099470A1
AR099470A1 ARP150100451A ARP150100451A AR099470A1 AR 099470 A1 AR099470 A1 AR 099470A1 AR P150100451 A ARP150100451 A AR P150100451A AR P150100451 A ARP150100451 A AR P150100451A AR 099470 A1 AR099470 A1 AR 099470A1
Authority
AR
Argentina
Prior art keywords
virus
poultry
liquid
vaccine
live
Prior art date
Application number
ARP150100451A
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR099470A1 publication Critical patent/AR099470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una vacuna estable líquida que comprende un virus vivo de aves de corral, un 5 - 40% (p/v) de alcohol de azúcar, y 0,15 a 0,75 M de un aminoácido seleccionado del grupo que consiste en arginina, ácido glutámico y glicina; en donde la vacuna estable líquida tiene un pH de 6,0 a 8,0; en donde el virus vivo de aves de corral se selecciona del grupo que consiste en un virus atenuado, un vector viral de aves de corral recombinante, y un vector viral recombinante de un virus de aves de corral atenuado; y en donde el vector viral de aves de corral recombinante o el vector viral recombinante de un virus atenuado de aves de corral pueden codifican adicionalmente un antígeno heterólogo. Reivindicación 2: La vacuna estable líquida de la reivindicación 1 en donde el alcohol de azúcar es sorbitol. Reivindicación 3: La vacuna estable líquida de la reivindicación 2 en donde el aminoácido es arginina. Reivindicación 4: La vacuna estable líquida de la reivindicación 3, en donde el virus vivo de aves de corral se selecciona del grupo que consiste en un Virus de Bronquitis lnfecciosa de Aves de Corral (IBV), Virus de la Enfermedad de Bursitis infecciosa (IBDV), Virus de la Enfermedad de Newcastle (NDV), Virus de la enfermedad de Marek (MDV), metapneumovirus aviar (aMPV), Herpesvirus de pavos (HVT), y cualquier combinación de los mismos. Reivindicación 18: La vacuna estable líquida de la reivindicación 4 que comprende además una bacteria. Reivindicación 19: La vacuna estable líquida de la reivindicación 18 en donde la bacteria se selecciona del grupo que consiste en Pasteurella multocida atenuada viva, Salmonella enteritidis atenuada viva, Avibacterium paragallinarum atenuado vivo, Mycoplasma gallisepticum atenuado vivo, Clostridium perfringens vivo, y cualquier combinación de los mismos. Reivindicación 21: Un método de vacunación de un ave contra el Virus de la Bronquitis lnfecciosa (IBV), Virus de la Enfermedad de Bursitis lnfecciosa (IBDV), Virus de la Enfermedad de Newcastle (NDV), Virus de la enfermedad de Marek (MDV), un Metapneumovirus Aviar (aMPV) o Herpesvirus de pavos (HVT), que comprende la administración al ave de la vacuna estable líquida de la reivindicación 17. Reivindicación 22: El método de la reivindicación 21, en donde dicha administración se realiza mediante inyección subcutánea. Reivindicación 23: Un método de vacunación de un ave contra un virus de las aves de corral que comprende la administración al ave de la vacuna estable líquida de la reivindicación 1. Reivindicación 24: El método de la reivindicación 23, en donde dicha administración se lleva a cabo mediante pulverización o alimentación. Reivindicación 25: Un método de fabricación de una vacuna estable líquida que comprende la combinación de una cantidad terapéuticamente eficaz de un virus vivo atenuado de aves de corral con un 5 - 40% (p/v) de alcohol de azúcar, y 0,15 a 0,75 M de arginina; en donde la vacuna estable líquida tiene un pH de 6,0 a 8,0. Reivindicación 28: La vacuna estable líquida de las reivindicaciones 1, 2, 26, ó 27 en donde el virus vivo atenuado de aves de corral se selecciona del grupo que consiste en un Virus de la Bronquitis lnfecciosa (IBV), Virus de la Enfermedad de Bursitis infecciosa (IBDV), Virus de la enfermedad de Newcastle (NDV), Virus de la enfermedad de Marek (MDV) y Herpes virus de pavos (HVT).
ARP150100451A 2014-02-17 2015-02-13 Vacunas de virus de aves de corral líquidas AR099470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461940627P 2014-02-17 2014-02-17

Publications (1)

Publication Number Publication Date
AR099470A1 true AR099470A1 (es) 2016-07-27

Family

ID=52473917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100451A AR099470A1 (es) 2014-02-17 2015-02-13 Vacunas de virus de aves de corral líquidas

Country Status (8)

Country Link
US (3) US9827305B2 (es)
EP (1) EP3107571B1 (es)
JP (1) JP2017505807A (es)
CN (1) CN105992593B (es)
AR (1) AR099470A1 (es)
MX (1) MX2016010651A (es)
RU (1) RU2016137119A (es)
WO (1) WO2015121463A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN114145879A (zh) * 2014-12-22 2022-03-08 美国乔治亚大学研究基金公司 用于禽类疫苗接种的系统及方法
CN105999281B (zh) * 2016-07-26 2019-02-19 河南后羿生物工程股份有限公司 禽类活病毒用冻干保护剂、制备方法及应用
WO2018218360A1 (en) * 2017-05-31 2018-12-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Vaccine against necrotic enteritis in poultry
AR113996A1 (es) 2017-12-22 2020-07-08 Intervet Int Bv Vacunas líquidas de virus envueltos vivos
MX2021011848A (es) * 2019-03-29 2021-10-22 Intervet Int Bv Estabilizacion de bacterias mollicutes vivas en una composicion liquida.
US11813322B2 (en) 2019-06-10 2023-11-14 Boehringer Ingelheim Animal Health USA Inc. Stabilized liquid live vaccine
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
AR127944A1 (es) 2021-12-23 2024-03-13 Intervet Int Bv Vacunas líquidas estabilizadas de virus vivos

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155589A (en) 1958-04-14 1964-11-03 Upjohn Co Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis
US3526696A (en) 1968-02-14 1970-09-01 Lilly Co Eli Shipping fever vaccine
GB1575155A (en) 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
PT71926B (en) 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JPS589688A (ja) 1981-07-06 1983-01-20 Toyobo Co Ltd 安定な酵素組成物
JPS6153227A (ja) 1984-08-23 1986-03-17 Biseibutsu Kagaku Kenkyusho:Kk 日本脳炎・豚パルボウイルス感染症混合生ワクチン
US4867975A (en) * 1988-01-27 1989-09-19 University Of Delaware Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
US5443959A (en) 1992-09-09 1995-08-22 Tokuyama Corporation Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof
EP0650734B1 (en) 1993-10-28 1999-03-10 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Pentavalent live viral vaccine
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5593824A (en) 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US5565318A (en) 1994-09-02 1996-10-15 Pharmacia Biotech, Inc. Room temperature stable reagent semi-spheres
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
NZ503463A (en) 1997-09-25 2002-10-25 Biotechnology Res & Dev Leukotoxin deletion mutant of Pasteurella haemolytica
CN1053590C (zh) 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
AU2003263390B2 (en) 2002-08-26 2008-12-18 Zoetis Services Llc Vaccine for respiratory and reproductive system infections in cattle
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
AU2004263813B8 (en) 2003-02-25 2008-09-11 Medimmune, Llc Methods of producing influenza vaccine compositions
PT1638598E (pt) 2003-07-02 2007-03-30 Biotechnology Res & Dev Mutantes acapsulares de deleção de hyae de p. multocida
EP1692279A4 (en) 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
CN101052714B (zh) * 2004-11-05 2012-01-11 威尔斯达特生物制剂公司 稳定性和滤过性有包膜病毒制剂
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1896610A2 (en) 2005-05-03 2008-03-12 Handylab, Inc. Lyophilized pellets
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
EP2004144A1 (en) 2005-12-02 2008-12-24 Stichting Katholieke Universiteit Method for obtaining hollow particles
US20070190163A1 (en) 2006-01-24 2007-08-16 Malaknov Michael P Technology for preparation of macromolecular microspheres
EA019345B1 (ru) 2007-03-05 2014-03-31 Кадила Хелзкэр Лимитед Композиции, содержащие конъюгаты пэг-интерферон-альфа и рафинозу в качестве криопротектора
DK2144998T3 (en) 2007-04-06 2017-04-10 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
BRPI0811161A2 (pt) 2007-05-18 2014-10-07 Medimmune Llc Conservação de materiais bioativos por espuma liofilizada.
SG182206A1 (en) 2007-06-14 2012-07-30 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
TWI436789B (zh) 2008-01-21 2014-05-11 Intervet Int Bv 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包
JP5689687B2 (ja) 2008-03-05 2015-03-25 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ アジュバント含有ワクチン組成物の安定化方法
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2010146598A2 (en) * 2008-11-07 2010-12-23 Serum Institute Of India Ltd. Stable, dried rotavirus vaccine, compositions and process for preparation thereof
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
WO2010059232A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
WO2010088552A1 (en) 2009-01-30 2010-08-05 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
TWI471127B (zh) 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
TWI468157B (zh) 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
JP5891175B2 (ja) 2009-12-11 2016-03-22 バインド セラピューティックス インコーポレイテッド 治療用粒子の凍結乾燥に対する安定製剤
PL2675475T3 (pl) 2011-02-17 2015-12-31 Boehringer Ingelheim Vetmedica Gmbh Nowy europejski szczep prrs
US20140017318A1 (en) 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗

Also Published As

Publication number Publication date
RU2016137119A3 (es) 2018-10-04
EP3107571A2 (en) 2016-12-28
CN105992593A (zh) 2016-10-05
US9827305B2 (en) 2017-11-28
WO2015121463A3 (en) 2015-10-08
US20180104328A1 (en) 2018-04-19
CN105992593B (zh) 2020-03-06
RU2016137119A (ru) 2018-03-22
US20190008950A1 (en) 2019-01-10
EP3107571B1 (en) 2019-04-03
JP2017505807A (ja) 2017-02-23
US20160346381A1 (en) 2016-12-01
WO2015121463A2 (en) 2015-08-20
MX2016010651A (es) 2016-11-08

Similar Documents

Publication Publication Date Title
AR099470A1 (es) Vacunas de virus de aves de corral líquidas
ES2635019T3 (es) Vacuna con vector del herpesvirus de pavo contra la gripe aviar en aves de corral
Baron et al. Recent advances in viral vectors in veterinary vaccinology
RU2014143830A (ru) Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц
RU2010136629A (ru) Способы и композиции для вакцинации домашней птицы
RU2014126375A (ru) Рекомбинантные векторы hvt, экспрессирующие антигены патогенов птиц и их применение
RU2019136150A (ru) Вакцины против рекомбинантного герпесвируса gallid 3, кодирующие гетерологичные антигены птичьего патогена
RU2011112932A (ru) Композиция, содержащая хитозан, для глазного введения вакцины (вакцин) птицам
RU2016137121A (ru) Вакцины против вирусов свиней, стабильные в жидкой форме
RU2016112951A (ru) Рекомбинанатные вирусы болезни марека и их применение
BR112013026661B1 (pt) composição de vacina, usos da mesma e método para produzir a referida composição
RU2018103145A (ru) Вирус утиного энтерита и его применение
RU2019102170A (ru) Вирус утиного энтерита и его применение
Peeters et al. Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus
Umar et al. Emerging threat of H9N2 viruses in poultry of Pakistan and vaccination strategy
RU2545530C2 (ru) Инактивированная вакцина для птицы
Kim et al. Pathogenesis of novel reassortant avian influenza virus A (H5N8) Isolates in the ferret
RU2016106419A (ru) Усиление иммунного ответа птиц, индуцированного вирусным вектором
RU2019137459A (ru) Вакцины на основе реовирусов птиц
Salman et al. Role of a locally prepared bivalent inactivated Infectious Bronchitis Virus (IBV) vaccine within vaccination program to control infectious bronchitis disease in layer chickens.
Ganapathy et al. Pros and Cons on Use of Live Viral Vaccines in Commercial Chicken Flocks
Fernandez et al. EFFICACY OF VAXXITEK™ AND A COMMERCIALLY AVAILABLE OIL-EMULSION NDV VACCINE ADMINISTRATED SIMULTANEOUSLY BY THE SUBCUTANEOUS ROUTE USING THE ACCUVAC™ TWINSHOT OR THE ONE-SHOT MACHINES TO VACCINATE DAY-OLD COMMERCIAL BROILERS
NURSYUWARI et al. STUDY ON LOCAL NEWCASTLE DISEASE VIRUS GENOTYPE VII AS CANDIDATE FOR DEVELOPMENT OF INACTIVATED VACCINE
Zute et al. IMMUNITY DYNAMICS AGAINST INFECTIOUS BRONHITIS IN VACCINATED COMMERCIAL LAYERS
Haghighi Khoshkhoo et al. Field Evaluation of a Live Avian Metapneumovirus Vaccine in Broiler Farm

Legal Events

Date Code Title Description
FB Suspension of granting procedure